Cost-effectiveness of the ReDIRECT/counterweight-plus weight management programme to alleviate symptoms of long COVID

IF 15.7 1区综合性期刊 Q1 MULTIDISCIPLINARY SCIENCES

Nature Communications Pub Date : 2025-07-01 DOI:10.1038/s41467-025-59909-6

Heather L. Fraser, Laura Haag, Naomi Brosnahan, Alex McConnachie, Janice Richardson, Caroline E. Haig, Tracy Ibbotson, Jane Ormerod, Catherine A. O’Donnell, Michael E. J. Lean, Naveed Sattar, David N. Blane, Emilie Combet, Emma McIntosh

{"title":"Cost-effectiveness of the ReDIRECT/counterweight-plus weight management programme to alleviate symptoms of long COVID","authors":"Heather L. Fraser, Laura Haag, Naomi Brosnahan, Alex McConnachie, Janice Richardson, Caroline E. Haig, Tracy Ibbotson, Jane Ormerod, Catherine A. O’Donnell, Michael E. J. Lean, Naveed Sattar, David N. Blane, Emilie Combet, Emma McIntosh","doi":"10.1038/s41467-025-59909-6","DOIUrl":null,"url":null,"abstract":"<p>Long-term effects of COVID-19 infection, termed Long COVID (LC), are associated with reduced quality of life. Symptoms associated with overweight/obesity overlap with and may aggravate those of LC. This paper reports the economic evaluation alongside the ReDIRECT Trial, which evaluated the impact of an evidence-based, remotely-delivered weight management programme on self-reported symptoms of LC in those living with overweight/obesity in the United Kingdom. Recruited participants (<i>n</i> = 234) were randomly allocated to the intervention group (weight management) or control group (usual care). Incremental costs and Quality-Adjusted Life Years (QALYs) were calculated using intervention cost, healthcare resource use and EQ-5D-5L data collected at baseline, three and 6 months. In this work, we show that the ReDIRECT intervention is likely cost-effective in improving LC symptoms from an NHS/PSS perspective, compared to usual care (Incremental Cost-Effectiveness Ratio of £14,754/QALY). Adopting a broader societal perspective, the intervention becomes potentially cost saving compared to usual care.</p>","PeriodicalId":19066,"journal":{"name":"Nature Communications","volume":"25 1","pages":""},"PeriodicalIF":15.7000,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Nature Communications","FirstCategoryId":"103","ListUrlMain":"https://doi.org/10.1038/s41467-025-59909-6","RegionNum":1,"RegionCategory":"综合性期刊","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"MULTIDISCIPLINARY SCIENCES","Score":null,"Total":0}

引用次数: 0

Abstract

Long-term effects of COVID-19 infection, termed Long COVID (LC), are associated with reduced quality of life. Symptoms associated with overweight/obesity overlap with and may aggravate those of LC. This paper reports the economic evaluation alongside the ReDIRECT Trial, which evaluated the impact of an evidence-based, remotely-delivered weight management programme on self-reported symptoms of LC in those living with overweight/obesity in the United Kingdom. Recruited participants (n = 234) were randomly allocated to the intervention group (weight management) or control group (usual care). Incremental costs and Quality-Adjusted Life Years (QALYs) were calculated using intervention cost, healthcare resource use and EQ-5D-5L data collected at baseline, three and 6 months. In this work, we show that the ReDIRECT intervention is likely cost-effective in improving LC symptoms from an NHS/PSS perspective, compared to usual care (Incremental Cost-Effectiveness Ratio of £14,754/QALY). Adopting a broader societal perspective, the intervention becomes potentially cost saving compared to usual care.

Abstract Image

查看原文本刊更多论文

重定向/配重加体重管理方案缓解长期COVID症状的成本效益

COVID-19感染的长期影响，称为长COVID (LC)，与生活质量下降有关。与超重/肥胖相关的症状与LC重叠并可能加重。本文报道了经济评估和ReDIRECT试验，该试验评估了英国超重/肥胖患者自我报告的LC症状的循证远程体重管理方案的影响。招募的参与者（n = 234）被随机分配到干预组（体重管理）或对照组（常规护理）。使用基线、3个月和6个月时收集的干预成本、医疗资源使用和EQ-5D-5L数据计算增量成本和质量调整生命年（QALYs）。在这项工作中，我们表明，从NHS/PSS的角度来看，与常规护理相比，ReDIRECT干预在改善LC症状方面可能具有成本效益（增量成本-效果比为14,754英镑/QALY）。从更广泛的社会角度来看，与常规护理相比，这种干预可能会节省成本。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Nature Communications Biological Science Disciplines-

CiteScore

24.90

自引率

2.40%

发文量

6928

审稿时长

3.7 months

期刊介绍： Nature Communications, an open-access journal, publishes high-quality research spanning all areas of the natural sciences. Papers featured in the journal showcase significant advances relevant to specialists in each respective field. With a 2-year impact factor of 16.6 (2022) and a median time of 8 days from submission to the first editorial decision, Nature Communications is committed to rapid dissemination of research findings. As a multidisciplinary journal, it welcomes contributions from biological, health, physical, chemical, Earth, social, mathematical, applied, and engineering sciences, aiming to highlight important breakthroughs within each domain.